Network Perspectives on HDM2 Inhibitor Chemotherapy Combinations

Current Pharmaceutical Design

Volumn 17, Issue 6, 2011, Pages 640-652

  Azmi, Asfar S ^a   Beck, Frances W J ^b   Sarkar, Fazlul H ^a   Mohammad, Ramzi M ^b  

^a Department of Pathology ^*  (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Chemotherapy; Combination therapy; HDM2; HDM2 inhibitors; Network modeling; P53; Systems biology; Tailored therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DASATINIB; DOXORUBICIN; FLUDARABINE; MI 219; MI 319; NUTLIN 3; OXALIPLATIN; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53; RESVERATROL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; DRUG DESIGN; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; GENE EXPRESSION PROFILING; HUMAN; NONHUMAN; PANCREAS ADENOCARCINOMA; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 79953657877     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161211795222612     Document Type: Review

References (116)

1. Collavin L, Lunardi A, Del SG. P53-family proteins and their regu-lators: hubs and spokes in tumor suppression. Cell Death Differ 2010; 17(6): 901-11.
2. Levine AJ. The p53 tumor-suppressor gene. N Engl J Med 1992; 326(20): 1350-2.
3. Wang TH, Wang HS. p53, apoptosis and human cancers. J Formos Med Assoc 1996; 95(7): 509-22.
4. He G, Siddik ZH, Huang Z, et al. Induction of p21 by p53 follow-ing DNA damage inhibits both Cdk4 and Cdk2 activities. Onco-gene 2005; 24(18): 2929-43.
5. Bartek J, Lukas J. Pathways governing G1/S transition and their response to DNA damage. FEBS Lett 2001; 490(3): 117-22.
6. Bringold F, Serrano M. Tumor suppressors and oncogenes in cellu-lar senescence. Exp Gerontol 2000; 35(3): 317-29.
7. Amaral JD, Xavier JM, Steer CJ, Rodrigues CM. The role of p53 in apoptosis. Discov Med 2010; 9(45): 145-52.
8. Venot C, Maratrat M, Dureuil C, Conseiller E, Bracco L, Debuss-che L. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J 1998; 17(16): 4668-79.
9. Venot C, Maratrat M, Sierra V, Conseiller E, Debussche L. Defini-tion of a p53 transactivation function-deficient mutant and charac-terization of two independent p53 transactivation subdomains. On-cogene 1999; 18(14): 2405-10.
10. Harms KL, Chen X. The C terminus of p53 family proteins is a cell fate determinant. Mol Cell Biol 2005; 25(5): 2014-30.
11. Khanna KK, Keating KE, Kozlov S, et al. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet 1998; 20(4): 398-400.
12. Fabbro M, Savage K, Hobson K, et al. BRCA1-BARD1 complexes are required for p53Ser-15 phosphorylation and a G1/S arrest fol-lowing ionizing radiation-induced DNA damage. J Biol Chem 2004; 279(30): 31251-8.
13. Chen SS, Chang PC, Cheng YW, Tang FM, Lin YS. Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function. EMBO J 2002; 21(17): 4491-9.
14. Yan C, Boyd DD. ATF3 regulates the stability of p53: a link to cancer. Cell Cycle 2006; 5(9): 926-9.
15. Leu JI, Dumont P, Hafey M, Murphy ME, George DL. Mitochon-drial p53 activates Bak and causes disruption of a Bak-Mcl1 com-plex. Nat Cell Biol 2004; 6(5): 443-50.
16. Giebler HA, Lemasson I, Nyborg JK. P53 recruitment of CREB binding protein mediated through phosphorylated CREB: a novel pathway of tumor suppressor regulation. Mol Cell Biol 2000; 20(13): 4849-58.
17. Watcharasit P, Bijur GN, Zmijewski JW, et al. Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage. Proc Natl Acad Sci USA 2002; 99(12): 7951-5.
18. Akakura S, Yoshida M, Yoneda Y, Horinouchi S. A role for Hsc70 in regulating nucleocytoplasmic transport of a temperature-sensitive p53 (p53Val-135). J Biol Chem 2001; 276(18): 14649-57.
19. Chen D, Li M, Luo J, Gu W. Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. J Biol Chem 2003; 278(16): 13595-8.
20. Kondo S, Lu Y, Debbas M, Lin AW, Sarosi I, Itie A et al. Charac-terization of cells and gene-targeted mice deficient for the p53- binding kinase homeodomain-interacting protein kinase 1 (HIPK1). Proc Natl Acad Sci USA 2003; 100(9): 5431-6.
21. Hofmann TG, Moller A, Sirma H, Zentgraf H, Taya Y, Droge W et al. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol 2002; 4(1): 1-10.
22. Moehlenbrink J, Bitomsky N, Hofmann TG. Hypoxia suppresses chemotherapeutic drug-induced p53 Serine 46 phosphorylation by triggering HIPK2 degradation. Cancer Lett 2010; 292(1): 119-24.
23. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degra-dation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92(6): 725-34.
24. Badciong JC, Haas AL. MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination. J Biol Chem 2002; 277(51): 49668-75.
25. Bai L, Merchant JL. ZBP-89 promotes growth arrest through stabi-lization of p53. Mol Cell Biol 2001; 21(14): 4670-83.
26. Kastan MB. Wild-type p53: tumors can't stand it. Cell 2007; 128(5): 837-40.
27. Campling BG, el-Deiry WS. Clinical implications of p53 mutations in lung cancer. Methods Mol Med 2003; 75: 53-77.
28. Bosari S, Viale G. The clinical significance of p53 aberrations in human tumours. Virchows Arch 1995; 427(3): 229-41.
29. Li FP, Fraumeni JF, Jr. Collaborative interdisciplinary studies of p53 and other predisposing genes in Li-Fraumeni syndrome. Cancer Epidemiol Biomarkers Prev 1994; 3(8): 715-7.
30. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253(5015): 49-53.
31. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human can-cers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010; 2(1): a001008.
32. Bottger A, Bottger V, Garcia-Echeverria C, et al. Molecular char-acterization of the hdm2-p53 interaction. J Mol Biol 1997; 269(5): 744-56.
33. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009; 9(12): 862-73.
34. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387(6630): 296-9.
35. Momand J, Wu HH, Dasgupta G. MDM2--master regulator of the p53 tumor suppressor protein. Gene 2000; 242(1-2): 15-29.
36. Cahilly-Snyder L, Yang-Feng T, Francke U, George DL. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet 1987; 13(3): 235-44.
37. Ries S, Biederer C, Woods D, Shifman O, Shirasawa S, Sasazuki T et al. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 2000; 103(2): 321-30.
38. Wunder JS, Eppert K, Burrow SR, Gokgoz N, Bell RS, Andrulis IL. Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas. On-cogene 1999; 18(3): 783-8.
39. Toi M, Saji S, Suzuki A, Yamamoto Y, Tominaga T. MDM2 in Breast Cancer. Breast Cancer 1997; 4(4): 264-8.
40. Asomaning K, Reid AE, Zhou W, et al. MDM2 promoter polymor-phism and pancreatic cancer risk and prognosis. Clin Cancer Res 2008; 14(12): 4010-5.
41. Mancini F, Gentiletti F, D'Angelo M, Giglio S, Nanni S, D'Angelo C et al. MDM4 (MDMX) overexpression enhances stabilization of stress-induced p53 and promotes apoptosis. J Biol Chem 2004; 279(9): 8169-80.
42. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregula-tory feedback loop. Genes Dev 1993; 7(7A): 1126-32.
43. Picksley SM, Lane DP. The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays 1993; 15(10): 689-90.
44. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispen-sable for p53 activation. Cell 2008; 133(4): 612-626.
45. Ashcroft M, Ludwig RL, Woods DB, et al. Phosphorylation of HDM2 by Akt. Oncogene 2002; 21(13): 1955-62.
46. Bothner B, Lewis WS, DiGiammarino EL, Weber JD, Bothner SJ, Kriwacki RW. Defining the molecular basis of Arf and Hdm2 in- teractions. J Mol Biol 2001; 314(2): 263-77.
47. DiGiammarino EL, Filippov I, Weber JD, Bothner B, Kriwacki RW. Solution structure of the p53 regulatory domain of the p19Arf tumor suppressor protein. Biochemistry 2001; 40(8): 2379-86.
48. Ito A, Kawaguchi Y, Lai CH, et al. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 2002; 21(22): 6236-45.
49. Ochocka AM, Kampanis P, Nicol S, et al. FKBP25, a novel regula-tor of the p53 pathway, induces the degradation of MDM2 and ac-tivation of p53. FEBS Lett 2009; 583(4): 621-6.
50. Dias SS, Hogan C, Ochocka AM, Meek DW. Polo-like kinase-1 phosphorylates MDM2 at Ser260 and stimulates MDM2-mediated p53 turnover. FEBS Lett 2009; 583(22): 3543-8.
51. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible fac-tor 1alpha. Genes Dev 2000; 14(1): 34-44.
52. Balint E, Bates S, Vousden KH. Mdm2 binds p73 alpha without targeting degradation. Oncogene 1999; 18(27): 3923-9.
53. Colaluca IN, Tosoni D, Nuciforo P, et al. NUMB controls p53 tumour suppressor activity. Nature 2008; 451(7174): 76-80.
54. Clark PA, Llanos S, Peters G. Multiple interacting domains con-tribute to p14ARF mediated inhibition of MDM2. Oncogene 2002; 21(29): 4498-507.
55. Grossman SR, Perez M, Kung AL, et al. P300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell 1998; 2(4): 405-15.
56. Linke K, Mace PD, Smith CA, Vaux DL, Silke J, Day CL. Struc-ture of the MDM2/MDMX RING domain heterodimer reveals di-merization is required for their ubiquitylation in trans. Cell Death Differ 2008; 15(5): 841-8.
57. Zhang Y, Wolf GW, Bhat K, et al. Ribosomal protein L11 nega-tively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol 2003; 23(23): 8902-12.
58. Xu H, Zhang Z, Li M, Zhang R. MDM2 promotes proteasomal degradation of p21Waf1 via a conformation change. J Biol Chem 2010; 285(24): 18407-14.
59. Zhang Z, Li M, Wang H, Agrawal S, Zhang R. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on prolifera-tion, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci USA 2003; 100(20): 11636-41.
60. Zhang Z, Wang H, Li M, Agrawal S, Chen X, Zhang R. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem 2004; 279(16): 16000-6.
61. Zhang Z, Zhang R. p53-independent activities of MDM2 and their relevance to cancer therapy. Curr Cancer Drug Targets 2005; 5(1): 9-20.
62. Xu L, Pirollo KF, Chang EH. Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. J Con-trol Release 2001; 74(1-3): 115-28.
63. Pirollo KF, Xu L, Chang EH. Non-viral gene delivery for p53. Curr Opin Mol Ther 2000; 2(2): 168-75.
64. Chang EH, Pirollo KF, Bouker KB. Tp53 gene therapy: a key to modulating resistance to anticancer therapies? Mol Med Today 2000; 6(9): 358-64.
65. Liu M, Li C, Pazgier M, et al. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms. Proc Natl Acad Sci USA 2010; 107(32): 14321-6.
66. Liu M, Pazgier M, Li C, Yuan W, Li C, Lu W. A left-handed solu-tion to peptide inhibition of the p53-MDM2 interaction. Angew Chem Int Ed Engl 2010; 49(21): 3649-52.
67. Li C, Pazgier M, Li C, et al. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions. J Mol Biol 2010; 398(2): 200-13.
68. Yu S, Qin D, Shangary S, et al. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem 2009; 52(24): 7970-3.
69. Shangary S, Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel ap-proach for cancer therapy. Annu Rev Pharmacol Toxicol 2009; 49: 223-41
70. Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 2008; 14(17): 5318-24.
71. Kussie PH, Gorina S, Marechal V, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation do- main. Science 1996; 274(5289): 948-53.
72. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303(5659): 844-8.
73. Vassilev LT. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 2004; 3(4): 419-21.
74. Stuhmer T, Chatterjee M, Hildebrandt M, et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 2005; 106(10): 3609-17.
75. Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leuke- mia therapy. Blood 2005; 106(9): 3150-9.
76. Vassilev LT. p53 Activation by small molecules: application in oncology. J Med Chem 2005; 48(14): 4491-9.
77. Klein C, Vassilev LT. Targeting the p53-MDM2 interaction to treat cancer. Br J Cancer 2004; 91(8): 1415-9.
78. Shangary S, Qin D, McEachern D, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 2008; 105(10): 3933-8.
79. Azmi AS, Philip PA, Almhanna K, Beck FW, Sarkar FH, Mo-hammad RM. MDM2 inhibitors for pancreatic cancer therapy. Mini Rev Med Chem 2010; 10(6): 518-26.
80. Azmi AS, Philip PA, Aboukameel A, et al. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. Curr Cancer Drug Targets 2010; 10(3): 319-31.
81. Mohammad RM, Wu J, Azmi AS, et al. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol Cancer 2009; 8: 115
82. Azmi AS, Philip PA, Beck, et al. MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene 2011; 30(1): 117-26.
83. Azmi AS, Aboukameel A, Banerjee S, et al. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pan-creatic cancer independent of p53 function. Eur J Cancer 2010; 46(6): 1122-1131.
84. El-Rayes BF, Zalupski MM, Shields AF, et al. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic can- cer. Invest New Drugs 2005; 23(6): 583-90.
85. El-Rayes BF, Zalupski MM, Shields AF, et al. Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pan- creatic cancer. J Clin Oncol 2003; 21(15): 2920-5.
86. Richter J, Saif MW. Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the 2010 ASCO Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 22-24, 2010. JOP 2010; 11(2): 139-43.
87. Coll-Mulet L, Iglesias-Serret D, Santidrian AF, et al. MDM2 an-tagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006; 107(10): 4109-14.
88. Secchiero P, Zerbinati C, di Iasio MG, et al. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 2007; 8(4): 395-403.
89. Cheok CF, Dey A, Lane DP. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination. Mol Cancer Res 2007; 5(11): 1133-45.
90. Peirce SK, Findley HW. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73. Int J Oncol 2009; 34(5): 1395-402.
91. Hori T, Kondo T, Kanamori M, et al. Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in hu-man sarcoma HOS cells and human colon cancer HCT116 cells. Cancer Lett 2010; 287(1): 98-108.
92. Zheng T, Wang J, Song X, et al. Nutlin-3 cooperates with doxoru-bicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways. J Cancer Res Clin Oncol 2010; 136(10): 1597-604.
93. Marimuthu P, Kaur K, Kandalam U, et al. Treatment of ovarian cancer cells with nutlin-3 and resveratrol combination leads to apoptosis via caspase activation. J Med Food 2011; 14(1-2): 46-52.
94. Zheng M, Yang J, Xu X, Sebolt JT, Wang S, Sun Y. Efficacy of MDM2 inhibitor MI-219 against lung cancer cells alone or in com-bination with MDM2 knockdown, a XIAP inhibitor or etoposide. Anticancer Res 2010; 30(9): 3321-31.
95. Volpato S, Ferrucci L, Secchiero P, et al. Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults. Atherosclerosis 2010.
96. Zheng T, Wang J, Chen X, et al. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cho- angiocarcinoma cell line with p53 mutation. Tumour Biol 2010; 31(4): 287-95.
97. Jordan F. Handbook of Biological Networks. Lecture Notes in Complex Systems-Vol. 10. Stefano Boccaletti, Vito Latora, and Yamir Moreno (Eds.). (2010, World Scientific Publishing Com-pany, Singapore.) GBP90.00 (hardcover), x + 441 pages. ISBN: 978-981-283-879-7. Artif Life 2011; 17(1): 69-71.
98. Aloy P, Russell RB. Taking the mystery out of biological networks. EMBO Rep 2004; 5(4): 349-50.
99. Khanin R, Wit E. How scale-free are biological networks. J Com-put Biol 2006; 13(3): 810-8.
100. Barabasi AL. Scale-free networks: a decade and beyond. Science 2009; 325(5939): 412-3.
101. Meulmeester E, Maurice MM, Boutell C, et al. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced de- stabilization of Hdmx and Hdm2. Mol Cell 2005; 18(5): 565-76.
102. Pujol A, Mosca R, Farres J, Aloy P. Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol Sci 2010; 31(3): 115-23.
103. Boran AD, Iyengar R. Systems pharmacology. Mt Sinai J Med 2010; 77(4): 333-44.
104. Jia J, Zhu F, Ma X, Cao Z, Li Y, Chen YZ. Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 2009; 8(2): 111-28.
105. Lu Y, Nikolovska-Coleska Z, Fang X, et al. Discovery of a nano-molar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strat-egy. J Med Chem 2006; 49(13): 3759-62.
106. Ray RM, Bhattacharya S, Johnson LR. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1. Apopto-sis 2011; 16(1): 35-44.
107. Lau LM, Nugent JK, Zhao X, Irwin MS. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Onco-gene 2008; 27(7): 997-1003.
108. van L, I, Lain S. Sirtuins and p53. Adv Cancer Res 2009; 102: 171-95.
109. Ricci F, Pucci S, Sesti F, Missiroli F, Cerulli L, Spagnoli LG. Modulation of Ku70/80, clusterin/ApoJ isoforms and Bax expres- sion in indocyanine-green-mediated photo-oxidative cell damage. Ophthalmic Res 2007; 39(3): 164-73.
110. Mancinelli F, Caraglia M, Budillon A, Abbruzzese A, Bismuto E. Molecular dynamics simulation and automated docking of the pro- apoptotic Bax protein and its complex with a peptide designed from the Bax-binding domain of anti-apoptotic Ku70. J Cell Biochem 2006; 99(1): 305-18.
111. Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH. Proof of concept: network and systems biology approaches aid in the dis-covery of potent anticancer drug combinations. Mol Cancer Ther 2010; 9(12): 3137-44.
112. Brummelkamp TR, Fabius AW, Mullenders J, et al. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol 2006; 2(4): 202-6.
113. DiTullio RA, Jr., Mochan TA, Venere M, et al. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively acti- vated in human cancer. Nat Cell Biol 2002; 4(12): 998-1002.
114. Yoshida E, Aratani S, Itou H, et al. Functional association between CBP and HNF4 in trans-activation. Biochem Biophys Res Com-mun 1997; 241(3): 664-9.
115. Faratian D, Clyde RG, Crawford JW, Harrison DJ. Systems pathol-ogy--taking molecular pathology into a new dimension. Nat Rev Clin Oncol 2009; 6(8): 455-64.
116. Kiemer L, Cesareni G. Comparative interactomics: comparing apples and pears? Trends Biotechnol 2007; 25(10): 448-54.